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Abstract: 
Marine derivatives are of great pharmaceutical interest as inhibitory compound and search of bioactive compounds from Marine 
organism which is relatively new to medicinal chemistry. Our main aim in the study is to screen possible inhibitors against CCR5 
which acts as co-receptor M-tropic HIV-1, through virtual screening of 122 Marine derived compounds from various organisms 
known to have biological activity. Homology Model of CCR5 was constructed using MODELLER and the Model was energy 
minimized and validated using PROCHECK to obtain a stable structure, which was further used for virtual screening of Marine 
derived compounds through molecular Docking studies using GOLD. The Docked complexes were validated and Enumerated 
based on the GOLD Scoring function to pick out the best Marine inhibitor based on GOLD score. Thus from the entire 122 
Marine compounds which were Docked, we got best 4 of them with optimal GOLD Score. (LAMIVUDINE: 45.0218, 
BATZELLINE-D: 44.3852.ACYCLOVIR: 43.1362 and THIIOACETAMIDE: 42.7412) Further the Complexes were analyzed 
through LIGPLOT for their interaction for the 4 best docked Marine compounds.  Thus from the Complex scoring and binding 
ability its deciphered that these Marine compounds could be promising inhibitors for M-tropic HIV-1 using CCR5 as Drug target 
yet pharmacological studies have to confirm it. 
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Background: 
In AIDS therapy, there are currently a number of 
compounds available for multiple targets approved by the 
FDA and in clinical trials, e.g. protease inhibitors, reverse 
transcriptase inhibitors (NRTI, NNRTI) and CCR5, CCR4, 
fusion inhibitors, among others [1-4]. CCR5 is a member 
of the serpentine-receptor superfamily [5] and is expressed 
by monocytes, memory T lymphocytes, and preferably by 
Th1 cells and NK cells [6–8].CCR5 act as a co-receptor for 
macrophage tropic(R5) strains of HIV-1 [9, 10] via 
interacting with viral envelope glycoprotein gp120, causing  
envelope fusion and viral entry [11–13]. Certain 
Individuals who are homozygous for an internal 32-bp 
deletion in the gene encoding CCR5 produce a truncated 
form of the receptor that is not expressed on the cell 
surface, providing a high degree of resistance to M-tropic 
strains of HIV-1 [14, 15]. The physiological Ligand of 
CCR5 has been shown to block the co-receptor activity of 
M-tropic HIV-1 [11, 16–18]. 
 
  In contrast, the viral chemokine vMIP-II [19], an 
antagonist of CCR5, has been shown to have limited virtue 
as an inhibitor of co-receptor activity [20]. This variation  
may be ascribed to the binding of these Ligand s to 
different regions of CCR5, indicating the importance of the 
N-terminal extracellular region (N-ter) and the second extra 
cellular loop (ECL2) in co-receptor activity [21, 22]. Both the 
N-ter and the body of CCR5 have been shown to affect the co-
receptor activity of CCR5 [23].  
 
The N-ter domain significance has been shown in several 
studies, which entangle specific acidic and aromatic residues in 
co-receptor activity [24–26]. Substitution of the N-ter regions of 
chemokine receptors, such as CCR1 or CCR2b, with that of 
CCR5 has been shown to allow virus fusion and entry [23, 27–
30]. However, replacement of the N-ter region of CCR5 with 
that of chemokine receptors CCR1 or CCR2b has not been 
found to abolish co-receptor activity considerably [23, 27–30], 
indicating that both regions play vital roles in co-receptor 
activity. Ligand  binding and HIV-1 entry are also affected by 
the posttranslational sulfation of Y10 and Y14 of the N-ter, 
which have been shown to bind gp120 at micromolar affinities 
when included in synthetic peptides [31, 32], contrasted by a 
complete lack of binding of the non-sulfated forms. Thus, two 
regions of CCR5 have been postulated to exhibit important 
functions in cell fusion, the N-ter domain, and the extracellular 
loops  [29]. Transmembrane- spanning domains 4 [33] and 5 
[34] have been shown to play a role in co-receptor function, but 
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with gp120, or are important for regulating receptor 
conformation.  
 
A small molecule inhibitor of CCR5 co-receptor function, 
TAK-779 [35], has been shown to require residues mapped 
to TM1, 2, 3, and 7 [36]. Other compounds such as SCH-C, 
SCH-351125, and SCH-350581, as well as members of 
another set of chemically unrelated small molecule 
inhibitors, 2-aryl-4-(piperidin-1-yl) butanamines and 1,3,4-
trisubstituted pyrrolidines, appear to utilize a non-identical 
overlapping binding site involving TMs 2, 3, 6, and 7 
[37,38]. Thus, it is likely that these CCR5 antagonists have 
an allosteric effect on receptor conformation, in contrast to 
direct blockade of the binding site for physiologic and 
pathologic Ligands.  
 
Similar to plant derived compounds for the therapeutic 
uses, Marine derived compounds do also have similar kind 
of effect from the pharmacological point of perspective and 
hence it’s been used in cure for many deadly diseases. 
Marine sources were not utilized to any extent until the mid 
20
th centaury the last 30 years has seen an explosive 
growth of natural products from Marine organisms and 
these products are invariably described with some sort of 
biological activity. The search of bioactive compounds from 
Marine organisms relatively a new field. However, the 
biodiversity of Marine environment far exceeds that of its 
terrestrial counter partner, So the oceans represents an 
enormous resource for new biologically Active compounds. 
There are 15 Marine natural products currently in clinical trails 
(Modern Drug discovery 2002) up to date. Our research work 
focus on virtual screening of such Marine compounds targeting 
HIV-1. 
 
The parameters used for genetic algorithm were population size 
(100), selection pressure (1.1), number of operations (100,000), 
number of islands (5), niche size (2), migrate (10), mutate (95) 
and cross-over (95). The default speed selection was used to 
avoid a potential reduction in docking accuracy. Fifty genetic 
algorithm runs with default parameter settings were performed 
without early termination. To estimate the protein-Ligand 
complexes, the scoring function, the entire sets of 122 Marine 
therapeutic compounds were docked against Modeled CCR5 
using GOLD [Genetic Optimization of Ligand Docking] 
version 2.1.2 was used to Screen for the possible inhibitory 
Marine compounds against CCR5 using GOLD Score. [44]. 
LIGPLOT  [45] was constructed for analyzing the interaction 
with in the Best Docked complex. 
 
 
Figure 1: (a) The final model of stable structure of CCR5; (b) Validation of the model using Ramachandran plot computed with 
the PROCHECK program with 86.4% of the residues in favored and allowed regions. 
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Figure 2: Identified active site of CCR5 where the inhibitors are likely to bind 
 
Methodology: 
Homology modeling of CCR5 
The Homology Model of Human CCR5 with Swiss-Prot 
ID: P51681 was generated using MODELLER [39] with 
ClustalW alignment of Bovine Rhodopsin sequence 
[accession number P02699] and its crystal structure [PDB: 
1F88] as Template [40] chosen from PDB BLAST hit. The 
obtained Model was validated using PROCHECK [41] and 
final Energy minimized using CHARMm to obtain stable 
structure for further studies. 
 
Active site identification 
After the final Model was built, the possible Active sites of 
CCR5 were identified using Discovery Studio 2.0 [42] 
using the option Find site from Receptor Cavities.  
 
Ligand generation and optimization  
Marine Therapeutic compounds were gathered from 
Marine bioactive database [43] and 3D structures were 
generated using Discovery Studio 2.0[42] further the 
compounds were submitted for Ligand Minimization using 
CHARMm Forcefield with Smart Minimizer Algorithm 
Steps 1000 and Optimized. 
 
Virtual screening of marine compounds against CCR5 
using molecular docking 
The Ligand s, including all hydrogen atoms, were built and 
minimized using Discovery studio 2.0 and GOLD [Genetic 
optimization for Ligand  Docking] version 2.1.2 [44] was used 
for Docking the entire 122 set of Marine compounds [43]. The 
Active site was defined as the collection of protein residues 
enclosed within a 15 Å radius sphere. The annealing parameters 
for Van der Waals and hydrogen bonding were set to 4.0 Å and 
2.5 Å respectively.  
 
Results and discussion: 
A confidence level sequence identity gives a reliable alignment 
between the target sequence and template structure. Our PDB 
BLAST Hit for CCR5 target sequence gave a best hit of 
Rhodopsin crystal structure (PDB: 1F88) .The Initial Model 
thus generated using MODELLER. Structurally conserved 
regions (SCRs) for the Model and the template were determined 
by multiple sequence alignment. Coordinates from the reference 
protein (1F88) to the SCRs, structurally variable regions 
(SVRs), N-terminal and C-terminal were assigned to the target 
sequence based on the satisfaction of spatial restraints. All side 
chains of the Modeled protein were set by rotamers. Thus, the 
obtained Model was refined by Energy minimization using 
CHARMm force field and the final stable structure of CCR5 is 
obtained (Figure 1). 
 
After the refinement process, validation of the Model was 
carried out using Ramachandran plot calculations computed 
with the PROCHECK program. Altogether 86.4% of the 
residues were in favored and allowed regions (Figure 1). From Bioinformation by Biomedical Informatics Publishing Group          open access 
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previous experimental evidence and from Figure 1 we 
come know that CCR5 receptor has 7 transmembrane 
helices with extracellular N-terminal end  and intracellular 
C -terminal loop where in the extracellular loop plays an 
important role in the binding Gp120 to the co-receptor  for 
M-tropic HIV-1  entry and which in intern also inhibitory 
site for the Antagonist. For the built CCR5 final Model the 
possible Active sites were identified using Discovery 
Studio 2.0. Fourteen possible Active sites were obtained 
using the option Find site from Receptor Cavities. These 
pockets were compared with the Active site of the template 
(Bovine Rhodepsin PDB: 1f88) and by careful analysis of 
the entire predicted 14 Active sites, we found that 12
th predicted 
Active site (shown in Figure 2) with residues Asp2, pro8, 
Asn13, Tyr14, Tyr15, Thr16, Gln21 of CCR5 were similar to 
that of the catalytic site in 1f88 and Therefore its chosen as the 
most biologically favorable site for Docking study and other 
Identified Active sites were neglected. (Figure 2) A set of 122 
Marine Bioactive compounds were gathered from Marine 
bioactive database  and 3D structures were generated using 
Discovery Studio 2.0 further Energy Minimized using 
CHARMm Forcefield and using Ligand s preparation option the 
best conformation were  prepared  for all 122 Marine 
compounds. 
 
 
Figure 3: Receptor – ligand interaction is shown. (a)  LAMIVUDINE O7 hydrogen bonded with extra cellular loop residue 
Asp11 OH at a distance of    3.29 Å and Gln4, Pro8, Asn13, Tyr14 and Tyr15 are non-ligand residues involved in hydrophobic 
contact(s). (b) BATZELLINE O7 hydrogen bonded with Extracellular loop residue Asp2 NH at a distance of    2.88 Ǻ and Gln4, 
Asn13 and Tyr15 are non-ligand residues involved in hydrophobic contact(s).  (c) ACYCLOVIR O10 hydrogen bonded with 
NH and with OH of Asn13 at a distance of 2.38 Ǻ and 3.21 Ǻ. Like wise NH hydrogen bonded with Gln4 at distance of 2.35 Ǻ 
where as Met1, Pro8, Thy14 and Thy15 are non-ligand residues involved in hydrophobic contact(s). (d) THIIOACETAMIDE 
S3 hydrogen bonded with N of Asn13 at distance of 2.71 Ǻ and OH   hydrogen bonded with N of Gln4 at distance of 3.13 Ǻ and 
NH hydrogen bonded with N at a distance of 2.71 Ǻ where Asp2, Pro8, Thy14 and Thy15 are non-ligand residues involved in 
hydrophobic contact(s). 
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Docking of marine compounds to CCR5  
Docking of all 122 Marine compounds with Human CCR5 
Model was performed using GOLD, which was set to 50 
cycles of run without constraints between the Ligand s and 
the specific amino acids of the pocket. The algorithm 
exhaustively searches the entire rotational and translational 
space of the Ligand with respect to the receptors. The 
flexibility of the Ligand is given by dihedral angle 
variations. The various solutions evaluated by a score, 
which is equivalent to the absolute value of the total energy 
of the Ligand in the protein environment. The best Four 
Docking solution's GOLD score for each Compound were 
considered. It’s noted that all the GOLD scores are very 
similar in all the top three solutions for each Marine 
compound. The GOLD score and RMSD differences 
between the consecutive top three runs of  each best   
Docked Marine inhibitor is zero and this indicates the 
stabilization of particular inhibitor at the Active site. Out of 
122 Marine compounds submitted for GOLD Docking run 
against Modeled Human CCR5 and we obtained 4 Marine 
compounds with optimal solution with Gold score Shown 
in Table [Rest of data not shown]  (Table 1 in 
Supplementary material). 
To understand the interaction between CCR5 and the four 
Marine compounds, Complexes were generated using the 
GoldMine suite for the outputs of Gold solutions. 
LIGPLOT were run for all the four complexes. It is evident 
from the analysis of the Docked complex that Marine 
inhibitors are located in the center of the Active site, and is 
stabilized by hydrogen bonding interactions and are bound 
in between 1
st and 4
th α-helices Extracellular loop  arresting 
the co-receptor activity of CCR5 for the entry of M-tropic 
HIV-1. (Figure 3)  Through the interaction analysis, we 
know that Gln4, Asn13 and Thy14 are important anchoring 
residues for CCR5 and are the main contributors towards 
compound interaction. Though the interaction energy does 
not include the contribution from the water or the extended 
compound structure, this preliminary data along with the 
list of hydrogen bond interactions between the compounds 
and the Active site residues clearly supports that Gln4, 
Asn13 andThy14 are more preferred residues in binding.  
 
Conclusion: 
CCR5 is one of the most recent potent Drug target for 
HIV1. In this work, we have constructed a 3D Model of 
CCR5, using the MODELLER software and obtained a 
refined Model after energy minimization. The final refined 
Model was further assessed by PROCHECK program, and 
the results show that the Model was stable and reliable. 
The stable Model was further used for Virtual Docking of 
Marine Compounds. Docking results indicate that out of 
122 Marine compounds, there were Four inhibitory 
compounds for CCR5 as Target for HIV-I. As it’s well 
known, hydrogen bonding plays an important role for the 
structure and function of biological molecules, especially 
for Inhibition in a complex. Thus our study confirms 
LAMIVUDINE, BATEZELLINE-D, ACYCLOVIR and 
THIOACETAMIDE are potential inhibitor for CCR5 as target 
for HIV-I forming a hydrogen bonding and with non-bonded 
interaction to act as a drug candidate yet Pharmacological study 
will yet confirm it to be promising.  
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S. No  Marine compound  IUPAC name  Molecular formula 
and  Mol. Wt. 
Gold score 
 
1 
 
LAMIVUDINE 
4-amino-1-[(2R,5S)-2-
(hydroxymethyl)-1,3-
oxathiolan-5-
yl]pyrimidin-2-one 
C8H11N3O3S 
229.257g/mol 
 
45.0218 
 
2 
 
BATZELLINE -D 
 
Pyrrolo[4,3,2-
de]quinoline-7,8-dione, 
6-chloro-1,3,4,5-
tetrahydro- 
 
C10H7ClN2O2 
222.628g/mol 
 
44.3852 
3  
ACYCLOVIR 
2-amino-9-(2-
hydroxyethoxymethyl)-
3H-purin-6-one 
C8H11N5O3 
225.205g/mol 
 
43.1362 
4  
THIIOACETAMIDE 
 
Ethanethioamide 
C2H5NS 
75.132800 g/mol 
 
42.7412 
Table 1: Table shows the best docked Marine compounds and its GOLD score. 
 
 